Program Overview

World Ballroom
Time Title
09.00 - 10.00
Opening Ceremony

• Ponlapat Rojnuckarin (TSH)
• Antonio Almeida (EHA)
• Gianluca Gaidano (EHA)
• Suradej Hongeng (TSH)

10.00 - 11.45
Session 1 : Lymphoid Malignancies

Chairs:  Rakhee Kar (India)  |  MHFA Rahman (Malaysia)

•    Updates of diffuse large B cell lymphoma and follicular lymphoma
Speaker : Gianluca Gaidano (Italy)
•    CLL genes and microenvironment
Speaker : Dimitar Efremov (Italy)
•    COVID and SARS-CoV2 vaccination in lymphoma patients
Speaker : Sabine Haggenburg (The Netherlands)
•    Panel Discussion
Speaker : All Speakers

11.45 - 13.15
12.00 - 13.00
Lunch Symposium I : Roche Thailand

Chair: Wichean Mongkonsritragoon (Thailand)

•    Advancements in treatment of Diffuse large B-cell lymphoma”
Speaker : Marek Trneny (Czech Republic)

13.15 - 15.00
Session 2 : Acute Leukemia

Chairs:  Pimjai Niparuck (Thailand)  |  Natasha Ali (Pakistan)

•    Molecular landscape in elderly AML
Speaker : Lars Bullinger (Germany)
•    Impact of measurable residual disease for precision medicine in AML
Speaker : Sylvie Freeman (United Kingdom)
•    Cellular Therapy in Pediatric Leukemias
Speaker :  Usanarat Anurathapan (Thailand)
•    Panel Discussion
Speaker : All Speakers

15.00 - 15.15
Coffee Break | Exhibition
15.15 - 17.00
Session 3: Red cell disorders & Bone marrow failure

Chairs:   Abdul Aziz (Bangladesh)  |  Angelina Mirasol (Philippines)

•    Guidelines on Use of NGS in the diagnosis of congenital anemias
Speaker : Noemi Roy (United Kingdom)
•    Fanconi anemia as a paradigm of clonal evolution in a deficient hematopoiesis
Speaker  : Jean Soulier (France)
•    Non-transfusion-dependent thalassemia: An update on complications and management
Speaker : Ali Taher (Lebanon)
•    Panel Discussion
Speaker : All Speakers

Janssen EHA2022 Sponsored Content-Optimizing treatment selection and sequencing for patients with multiple myeloma (MM) a precision medicine approach
Janssen EHA2022 Sponsored Content-Minimal residual disease (MRD): the big question mark in chronic lymphocytic leukemia (CLL)
Janssen EHA2022 Sponsored Content-Immunotherapies: Rising to the challenge of relapsed/refractory multiple myeloma (MM)
Janssen EHA2022 Sponsored Content-Immunotherapy: evolution or revolution in the cure of multiple myeloma